Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients Undergoing Hematopoetic Cell Transplantation (HCT)
You have been asked to participate in this research study because you have a diagnosis of multiple myeloma and have already agreed to participate in a research study where you will receive the chemotherapy drug, melphalan, followed by total marrow irradiation (TMI): 04064 - TANDEM HIGH-DOSE THERAPY WITH MELPHALAN AND TOTAL MARROW IRRADIATION (TMI) WITH PERIPHERAL BLOOD PROGENITOR CELL SUPPORT AND DEXAMETHASONE AND THALIDOMIDE MAINTENANCE: A PHASE I/II TRIAL. The purpose of this study is monitor side effects for the first two years after these therapies and to see if there are any relationships between side effects and the radiation therapy doses to certain organs in your body (heart, liver, lungs, kidneys, thyroid gland, and lens of the eyes). Your participation in this study is expected to last for 24 months. After your participation on this study, your medical condition will continue to be followed indefinitely.
Total marrow irradiation (TMI) using helical tomotherapy is a new way of delivering radiotherapy in patients undergoing bone marrow transplantation. The areas of the body containing more myeloma cells, such as the bone, are targeted with radiotherapy while at the same time radiation doses to normal organs are reduced compared to methods used in the past.
The reduction in dose to normal organs such as the lungs, heart, liver, kidneys, thyroid gland and lens of the eyes are predicted to reduce potential long term side effects. This study will monitor the side effects related to these organs for the first two years after TMI. This information will then be compared to the doses received to these organs to determine if there are any relationships between dose and the likelihood or severity of specific side effects.
COH Protocol Number : 07173
Principal Investigator : Wong, Jeffrey M.D.
Sponsor : City of Hope
BRIEF ELIGIBILITY CRITERIA :
Eligible Ages : >=18
Gender : Either
Prior Chemotherapy :
Brain Metastases :
Measurable Disease :